Skip to main content

Table 4 Differences in age and menopausea status at diagnosis across six-marker immunohistochemistry-defined subtypesb in the AMBER consortium

From: Frequency of breast cancer subtypes among African American women in the AMBER consortium

 

Age ≥50 years, n (%)

Age <50 years,n (%)

OR (95% CI)

Postmeno, n (%)

Premeno, n (%)

OR (95% CI)

Luminal A

305 (39)

207 (34)

1

300 (39)

204 (35)

1

Luminal B

195 (25)

138 (23)

1.04 (0.79–1.38)

194 (25)

135 (23)

1.02 (0.77–1.36)

ER-/HER2+

49 (6)

62 (10)

1.86 (1.23–2.82)

51 (7)

57 (10)

1.64 (1.08–2.30)

Basal-like

224 (29)

201 (33)

1.32 (1.02–1.71)

233 (30)

182 (31)

1.15 (0.88–1.49)

P value c

0.008

 

0.107

 

Unclassified

93

78

 

93

72

 
  1. Tumors with five-marker negative (n = 7), human epidermal growth factor 2 (HER2)-equivocal (n = 81), and missing biomarker (n = 83) status remained unclassified
  2. ER estrogen receptor, Postmeno postmenopausal, Premeno premenopausal
  3. aThere were 25 cases with missing data on menopause status
  4. bLuminal A: HR+, low Ki67; luminal B: HR+, high Ki67; ER-/HER2+: ER <10% and HER2-positive; basal-like: HR-, HER2- and (EGFR+ or CK5/6+)
  5. cChi-square test p value excludes unclassified cases